



XENOTHERA

PRESS RELEASE

Nantes, 3 April 2023

The French biotech XENOTHERA, on a mission with Business France in China

- from April 3rd to April 6th 2023 -

The biotech company [XENOTHERA](#), which since 2020 has developed an antibody treatment called XAV-19 for patients suffering from COVID, strongly supported by France (SGPI) and Europe (EIC), will travel to China at the beginning of April to meet local players.

As part of a trip organized by [Business France](#), XENOTHERA will be present in Shanghai on April 3rd and 4th and then in Beijing on April 5th and 6th. This will be an opportunity to discuss possible collaborations and partnerships with the majors of the Chinese pharmaceutical sector, on its entire portfolio of innovative medicines.

For four days, the national agency for the internationalization of the French economy, Business France, is accompanying a delegation of French companies from various sectors, including the biotech sector represented by XENOTHERA and its co-founder Odile Duvaux, who will be on site. One of the objectives of this mission is to advance strategic projects between France and China. To this end, Business France, which is responsible for the international development of companies and their exports, as well as for prospecting and welcoming international investments in France, has set up a tailor-made program and will also put the delegation's companies in touch with key players in China.

The particular situation in China with regard to COVID, and the therapeutic interest of XAV-19, an antibody active on all the variants that have been circulating since 2020, resulting from XENOTHERA's protected technology, make these meetings particularly promising for the company and for Chinese patients.

In addition to COVID, XENOTHERA will be able to consider collaborations on its entire portfolio. The company has an induction treatment for transplantation, LIS1, whose phase I/II clinical trial was completed in 2022, and which confirms its interest in patients receiving organ transplants. In addition, the French biotech has developed several cancer treatments that will be in the clinic as early as 2023, introducing powerful innovation in the field of solid tumors and certain lymphomas.

"It's an honor to be part of this delegation, of course. In addition, we know that China is a huge territory in which we have a long-standing interest, as we have natural scientific convergences with the technologies already developed there, particularly in transplantation. There is no doubt that these meetings with local pharmaceutical companies will enable us to forge lasting links and start fruitful collaborations," comments **Odile Duvaux, CEO of XENOTHERA.**

About XENOTHERA:

Founded in 2014, XENOTHERA is a Nantes-based biotech that develops new therapeutic modes in many fields (immunology, oncology, viral infections...). The company develops treatments based on a unique proprietary technology of "glyco-humanized polyclonal antibodies (GH-pAb)". Its technological platform is built on a dual expertise in genetics and immunology.

The biotech has a complete portfolio of products, including three products in clinic: LIS1, an immunosuppressant for solid organ transplantation; XAV-19, an anti-Covid treatment for patients with moderate disease; and XAB05, for the prevention and treatment of multi-drug resistant bacterial infections.

XENOTHERA, is part of the scientific and medical environment of the Pays de la Loire (France). The company has raised 43M€ since its creation, its main investors are the Pays de la Loire Region, BPI France and the European EIC Fund.

More information: www.xenothera.com

Follow XENOTHERA on social networks: [LinkedIn](#) [Twitter](#)

Media relations:

IZsoGOOD

Ingrid Zémor

+33 6 73 72 99 92

xenothera@izsogood.co